Emergence Therapeutics Launched to Develop Novel ADC Immuno-therapies to Treat High-need Cancers

Focus on best combination of validated targets and ADC technology to tackle hard to treat cancers

Duisburg, Germany – Marseille, France, 1 October 2019: Emergence Therapeutics AG today announced its incorporation by founders Jack Elands, Xavier Preville and Kurma Partners. Emergence Therapeutics is a new pan-European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high unmet need cancers. The company is based in Duisburg, Germany with a subsidiary in Marseille, France.

Dr. Jack Elands, Chief Executive Officer commented: “Recent developments show that ADC technology is maturing. ADCs now represent a significant opportunity to treat solid cancers of high unmet medical need. Emergence Therapeutics’ strategy is to develop novel ADCs to treat such cancers by selecting the best combination of validated targets and ADC technology. The company is completing the process of in-licensing key assets to embark on its first program.”

Dr. Peter Neubeck, investment director at Kurma partners added: “As an investor in early-stage opportunities Kurma is proud to be a co-founder of Emergence Therapeutics and help the company to secure further investments towards its goal of developing novel ADCs.”

Latest News

25/11/2020

Emergence Therapeutics Announces Bumped-up Follow-on Seed Round Financing

Financing enables company to embark on additional targets and expand ADC technology reach Duisburg, Germany – Marseille, France, 25 November 2020: Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of...

View Article >
10/03/2020

Emergence Therapeutics AG Announces Establishment of Scientific Advisory Board

Key Opinion Leaders bring many years of ADC development expertise to the company Duisburg, Germany - Marseille, France, 10 March 2020: Emergence Therapeutics today announced that is has established its Scientific Advisory Board (SAB) to support the company in its goal to develop novel and innovative antibody-drug-conjugates (ADCs).

View Article >
22/01/2020

Emergence Therapeutics AG Announces Key Hirings to Senior Management Team

Substantial experience in cancer targets, ADC technology as well as corporate finances and law Duisburg, Germany – Marseille, France, 22 January 2020: Emergence Therapeutics announced today that is has hired Florence Lhospice as Chief Development Officer and Carsten Dehning as Chief Financial Officer and member of the Executive Board to complement its management team. Dr....

View Article >